A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Actym Therapeutics, Inc.
Ikena Oncology
Sotio Biotech Inc.
NantCell, Inc.
ABM Therapeutics Corporation
Hoffmann-La Roche
Icahn School of Medicine at Mount Sinai
MacroGenics
Fore Biotherapeutics
Calando Pharmaceuticals